AI summary by TwinMind
The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris
Andrew Huberman
2h 37m 9s
Introduction and Etymology of Psychedelics
- Dr. Robin Carhart-Harris: distinguished professor neurology/psychiatry UCSF, leading psychedelics researcher
- Psychedelic etymology: coined 1956 by Humphry Osmond for National Academy Sciences meeting
- Replaced "psychotomimetics" (drugs mimicking psychosis)
- Ancient Greek: "psyche" (mind/soul) + "delos" (to reveal/make manifest)
- Osmond's ditty: "to fathom hell or soar angelic, just take a pinch of psychedelic"
- Definition debate: pharmacological (serotonin 2A receptor agonists) vs phenomenological (subjective experience)
- Classic psychedelics: LSD, psilocybin, DMT - all work via serotonin 2A receptor
Psychedelics and the Unconscious
- Psychedelics reveal aspects of psyche ordinarily not visible
- Different from blindsight (non-conscious processing below awareness threshold)
- Access personal unconscious: repressed memories, difficult relationships, trauma
- Access collective unconscious (Jung): transpersonal aspects of human psyche
- Historical use in psychotherapy: material emerges with strong emotional release, cathartic experiences, insights
- This "psyche-revealing" action is what makes classic psychedelics unique vs other compounds
Clinical Trial Methodology and Dosing
- Psilocybin dosing: 25mg therapeutic dose, 10mg comparison, 1mg placebo/microdose
- Magic mushroom conversion: ~1% psilocybin content by weight (1g mushroom ≈ 10mg psilocybin)
- Microdosing definition: sub-perceptible doses taken semi-regularly
- LSD: ~10-12 micrograms threshold
- Evidence for microdosing benefits currently thin/lacking compelling data
- Imperial College study: citizen science microdosing showed mostly placebo effects
- Those thinking they got microdose (but got placebo) performed as well as actual microdosers
Therapeutic Session Structure
- Standard protocol across sites: settled conditions, music throughout, eye masks
- Two therapists present (ideally mental health professionals)
- Music progression: spacious beginning → atmospheric build → emotional strings
- Music appears critical but hasn't been formally tested as variable
- "Psychedelic-therapy" (hyphenated): combination treatment with positive interaction
Journey Phases and "Letting Go"
- Initial phase: anxiety, struggle against drug effects, fear of losing mind/dying
- Core mantra: "Trust, let go, be open" (attributed to Bill Richards)
- Trust: therapeutic rapport (measured, predicts outcomes)
- Let go: readiness to surrender, not resist
- Be open: willingness to confront difficult material
- Student Harry Brouwer's research: early phase dominated by negative emotions, latter half different
- Initial struggle typically against general drug effects rather than specific content
Brain Changes and Connectivity
- Acute effects: increased global functional connectivity between brain modules
- Normally modular communication (visual system talks within visual system)
- Psilocybin: communication transcends modules, becomes inter-modular
- Effect correlates with subjective experience magnitude
- Replicated with LSD, upcoming DMT paper shows similar effects
- Computational modeling confirms serotonin 2A receptor activation causes this effect
Long-term Brain Changes
- Increased connectivity persists: seen day after and 3 weeks post-session
- Magnitude correlates with therapeutic improvement in depression
- Decreased modularity may represent more flexible brain functioning
- Depression analogy: stuck in rut, cut off from other modalities/world
- Healthy volunteers study: anatomical brain changes in white matter tracts
- Decreased axial diffusivity in prefrontal-thalamic/striatal tracts
- Similar to healthy brain development (opposite of aging/pathology)
- Improved cognitive flexibility, psychological well-being
Clinical Trial Results
Depression Trials
- Psilocybin vs escitalopram (Lexapro) trial: New England Journal Medicine 2022
- Two sessions typically, 1-3 weeks apart
- Expectancy analysis: pre-trial expectations predicted SSRI response but NOT psilocybin response
- Challenges idea that psychedelic therapy is "super placebo"
- Treatment-resistant depression: majority show initial improvement but many relapse by 3+ months
- Some patients from first trial still well, back at work, but majority relapsed
- Participants denied continued treatment post-trial due to legal restrictions
Other Conditions
- Anorexia trial: 3 sessions, 2 weeks apart, 19 patients completed
- Improved weight at long-term follow-up
- Very exciting preliminary results
- Fibromyalgia study: chronic generalized pain condition
- 8 patients treated, going very well
- Single dose with EEG monitoring
- Profound experiences reported, no specific pain focus during sessions
Integration and Long-term Practice
- Integration potentially lasts lifetime - "after the ecstasy, the laundry" (Jack Kornfield)
- Therapeutic teams can't provide lifetime support
- May become personal practice like meditation
- Some consider "psychedelic practice" similar to meditation practice
- Meditation/mindfulness as important complement: ability to "sit with rather than sit on"
- Repeated dosing may be needed for some conditions
DMT and Ego Dissolution
- DMT: "rocket ship" compared to psilocybin's "ship leaving port"
- Serotonin 2A agonist, less potent than psilocybin but effects when smoked/vaped are intense
- 5-methoxy-DMT: more reliable ego dissolution, less visual, more immersive
- Ego dissolution: breakdown of self/other boundaries
- Positive aspect: feeling interconnected with others/world
- Recognition that ego is mental construction
- Serotonin 2A receptors heavily expressed in "recent brain" (evolutionarily recent cortex)
- Classic psychedelics cause this, MDMA less so
- Cocaine opposite effect: ego inflation via dopamine system
MDMA Comparison and Combinations
- MDMA: empathogen, easier access to difficult material, more directionally positive
- Classic psychedelics: can be "aggressively" deep, sometimes overwhelming for trauma
- Underground therapists use psilocybin/MDMA combinations ("hippy flip")
- MDMA allows safer return to trauma without dissociation/flashbacks
- Limitation: may not go as deep as classic psychedelics
- Classic psychedelics offer "honesty" - hell as well as heaven
Current Legal Landscape and Future
MDMA Timeline
- MAPS completed two Phase III trials for PTSD
- ~67% remission rates, long-term benefits (years)
- FDA filing happening now, potential approval 2023-2024
- MAPS may become provider, therapist training requirements being determined
- Referral process unclear (psychiatrist vs GP)
Psilocybin Timeline
- Compass running Phase III trials for treatment-resistant depression
- Estimated completion ~2026
- Multiple research centers globally studying various conditions
- Groundswell of positive results across psychiatric disorders
Decriminalization vs Legalization
- Oakland: decriminalized, some head shops selling openly
- Churches claiming religious exemption
- Federal FDA approval needed for nationwide medical access
- Current participants can't access treatment post-trial legally
Risks and Safeguards
- Boundary crossing scandals in psychedelic therapy community
- Importance of proper training, standards, safeguards
- Fentanyl contamination in street psychedelics - serious safety concern
- Need to avoid repeating 1970s backlash that shut down research
- Balance needed as field develops rapidly
